Importantly, Figure 10 illustrates that the Myc Mito-Signature was also effective in both ER(+) (N=3,082; HR=1.81; p<1e-16) and ER(−)/basal (N=618; HR=1.53; p=0.00091) breast cancer populations, as well as in all breast cancer subtypes combined (N=3,951; HR=1.71; p<1e-16; See Supplementary Figure S1). The gene discussed is MYC; the disease is breast cancer.